Trial Profile
A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Epoetin beta; Filgrastim
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms HOVON89MDS
- 06 Dec 2016 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Results of pre-final evaluation (n=180) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 16 Jun 2009 New trial record